5.2 Mineralocorticoids hormone imbalance-associated oxidative stress According to numerous clinical and investigations in animal models, the most significant physiological mineralocorticoid, aldosterone, causes OS and inflammation in patients with chronic and stable heart failure (67)
The WHO estimates it affects between 1020% of people infected with SARS-CoV-2 tens of millions globally.1 The symptoms are wide-ranging but cluster into recognizable patterns: Neurological: brain fog, cognitive impairment, headaches, sleep disruption Cardiovascular: chest pain, breathlessness, tachycardia (POTS), reduced exercise tolerance Immune: persistent low-grade inflammation, recurrent infections, autoimmune flares Musculoskeletal: post-exertional malaise (PEM), joint pain, muscle weakness Metabolic/endocrine: insulin dysregulation, thyroid disruption, adrenal fatigue signals Standard care rest, symptom management, antidepressants, rehabilitation programs helps some patients
Distinct effects of glutathione disulphide on the nuclear transcription factor kappa B and the activator protein-1
Clinical Perspective: How We Actually Use AOD-9604 In a medical setting, AOD-9604 is viewed as: A metabolic support tool A fat-specific signaling peptide A long-term adjunct, not a cycle drug It is often used: Continuously Alongside nutrition and movement Without mandatory breaks This aligns with the science
Research in rat models demonstrated accelerated healing of various tissue types including tendon, muscle, and skin in controlled laboratory settings
